The increasing prevalence of influenza viruses with resistance to approved antivirals highlights the need for new anti-influenza therapeutics. Here we describe the functional properties of hexamethylene amiloride (HMA)-derived compounds that inhibit the wildtype and adamantane-resistant forms of the influenza A M2 ion channel. For example, 6-(azepan-1-yl)-N-carbamimidoylnicotinamide (9) inhibits amantadine-sensitive M2 currents with 3-to 6-fold greater potency than amantadine or HMA (IC 50 5 0.2 vs. 0.6 and 1.3 mM, respectively). Compound 9 competes with amantadine for M2 inhibition, and molecular docking simulations suggest that 9 binds at site(s) that overlap with amantadine binding. In addition, tert-butyl 49-(carbamimidoylcarbamoyl)-29,3-dinitro-
Introduction
Viroporins are virally encoded transmembrane proteins that facilitate conduction of ions or small molecules and are required for efficient viral replication (Nieva et al., 2012) . Despite their small size (frequently ,100 amino acids), viroporins in many cases have evolved to function as highly regulated ion channels, which makes them attractive minimalist models of ion conductance and ion channel evolution (Pinto et al., 1992; Stouffer et al., 2008; Thiel et al., 2011; OuYang et al., 2013; OuYang and Chou, 2014) . The M2 viroporin of influenza A is a 97-amino-acid, type I transmembrane domain protein that forms a tetrameric ion channel that is proton-gated and proton-selective (Nieva et al., 2012) . After viral entry into host cells, M2 conducts protons from acidic host-cell endosomes to the virion interior to allow for uncoating and release of viral RNA. M2 on host-cell endosomal membranes is also observed in some cases to conduct protons to elevate secretory vesicle pH, thereby delaying egress of nascent virion particles and preventing viral hemagglutinin from adopting a nonfunctional, low pH conformation (Sugrue et al., 1990; Alvarado-Facundo et al., 2015) . The M2 ion channel of influenza B (B/M2) is a functional homolog of A/M2. It is 109 residues long and forms a homotetramer in the membrane like A/M2. Furthermore, B/M2 exhibits higher channel activity but shows a similar pH dependence in terms of its proton conductance; however, major differences exist between the two channels. Other than the HXXXW sequence motif crucial for channel activity, the two proteins share nearly no sequence homology, and unlike A/M2, the B/M2 proton conductance activity is entirely insensitive to amantadine and rimantadine (Mould et al., 2003; Wang et al., 2009) .
The compounds amantadine and rimantadine ( Fig. 1A ) are potent inhibitors of A/M2 proton conductance and licensed influenza antivirals (Hay et al., 1985; Pinto et al., 1992; Chizhmakov et al., 1996) ; however, M2 sequence changes that render resistance to adamantanes are now so prevalent that these compounds are no longer recommended for use (Fiore et al., 2011) . For example, more than 90% of transmissible adamantane-resistant influenza strains encode an M2 serine to asparagine mutation at position 31 (S31N). This mutation disrupts adamantane interactions within the M2 pore without adversely affecting ion channel activity (Hay et al., 1986; Belshe et al., 1988; Pinto et al., 1992; Bright et al., 2005; Stouffer et al., 2008; Balannik et al., 2010) . Thus, new small molecules that inhibit adamantane-resistant M2 are needed for both improved understanding of the chemical space and mechanisms by which M2 activity can be modified in addition to development of new influenza antivirals.
To date, few compounds are reported to act on the S31N form of M2 from influenza A. Furthermore, several proposed M2 inhibitors that are derived from established M2 inhibitors and act on subsets of drug-resistant influenza viruses in vitro instead confer antiviral activity through alternative mechanisms (Wang et al., 2013a; Kolocouris et al., 2014) , indicating that direct screening of M2 ion channel activity is necessary to identify bona fide M2(S31N) inhibitors. One of the most potent adamantane derivative for which detailed M2 current analysis is available, N-((5-(thiophen-2-yl)isoxazol-3-yl)methyl)-adamantan-1-amine (M2WJ352; Fig. 1A ), inhibits M2(S31N) but not wild-type (WT) M2 proton currents as measured by two electrode voltage clamp (TEVC) electrophysiology, with an IC 50 of 14 mM (Wang et al., 2013b) .
A separate class of compounds that remains poorly explored for anti-M2 activity is the acylguanidines (Kleyman and Cragoe, 1988; Gazina and Petrou, 2012) . Initially identified as potassium-sparing diuretics, acylguanidine-containing amilorides, and hexamethylene amiloride (HMA) in particular (Fig. 1B) , are inhibitors of multiple viroporins including those of hepatitis virus, HIV-1, and severe acute respiratory syndrome coronavirus (SARS-CoV) (Kleyman and Cragoe, 1988; Ewart et al., 2002; Premkumar et al., 2004; Pervushin et al., 2009; Gazina and Petrou, 2012) . HMA has also been reported to inhibit M2(WT) (IC 50 5 1.1 mM by TEVC) but not M2(S31N), whereas a related compound N-(5-(1-methyl-1H-pyrazol-4-yl)naphthalene-2-carbonyl)guanidine (BIT-225; Fig.  1B ) inhibits currents from the viroporins of hepatitis C and HIV-1 and shows promising activity in early clinical trials (Khoury et al., 2010; Luscombe et al., 2010; Gazina and Petrou, 2012) . Although additional acylguanidines, including ethyl-isopropyl amiloride (EIPA) and (6-(1-methylpryazol-4-yl)-2-napthoyl)guanidinium (BIT-314; Fig. 1B ), are also reported to have antiviral activity against multiple viroporins and viruses, their effects on M2 currents are not yet reported (Ewart et al., 2009; Gazina and Petrou, 2012) . Herein we describe an electrophysiology-driven approach to characterize the mechanism of and pharmacologically evaluate a series of acylguanidines and HMA-like derivatives on inhibition of WT and adamantane-resistant influenza M2 viroporins.
Materials and Methods
Chemistry. Detailed information for the synthesis and characterization of compounds 1-33 can be found in the Supplemental Material. M2WJ352 was synthesized as described previously (Wang et al., 2013b) . Amantadine hydrochloride, 5-(N,N-hexamethylene)amiloride, 5-(N-ethyl-N-isopropyl)amiloride, and 1-benzoylguanidine were purchased from Sigma-Aldrich (St. Louis, MO).
Electrophysiology. The tsA-201 cells, a derivative of the HEK 293T cell line, or ltk-murine fibroblast (LM) cells were cultured in modified Eagle's medium plus 10% fetal calf serum, 100 U/ml penicillin, and 100 mg/ml streptomycin (MEM 1 medium). cDNA sequences encoding full-length M2 were derived from the A/Hong Kong/1073/99(H9N2) or B/Lee/1940 references sequence and contained an N-terminal FLAG-tag plus 3 (Gly) repeat linker. This tag was used to confirm M2(WT) expression on the cell surface of transfected cells by immunocytochemistry (Supplemental Fig. 1 ). M2 sequences were cloned into the pcDNA3 plasmid and transiently cotransfected with a pcDNA3 plasmid encoding green fluorescent protein (GFP) into tsA-201 cells using standard transfection protocols (Lipofectamine 2000; Life Technologies, Waltham, MA); 24-48 hours after transfection, single GFP-positive cells were perfused continuously at 3-5 ml/min with external (bath) solution containing (in mM): 150 NMDG, 10 HEPES, 10 D-glucose, 2 CaCl 2 , 1 MgCl 2 buffered at pH 7.4. For low external pH (pH o 5.9 or 5.5) solution, HEPES was replaced by MES. Patch electrodes were pulled from thin-walled borosilicate glass (World Precision Instruments, Sarasota, FL) and fire-polished before filling with standard pipette solution containing (in mM): 140 NMDG, 10 EGTA, 10 HEPES, and 1 MgCl 2 buffered at pH 7.2 or pH 6.0 (10 mM MES). M2 currents were detected in .90% of GFP-positive cells assayed during the course of the study.
Voltage-clamp experiments were performed with an Axopatch 200B amplifier (Molecular Devices, Sunnyvale, CA) connected to a Digidata1322A 16-bit digitizer. Pipettes typically had a resistance of 3-5 MV. Data were acquired with pCLAMP9.2 software (Molecular Devices) sampled at 10-kHz and low-pass filtered at 5 kHz. The standard voltage protocol consisted of holding a cell at 240 mV, followed by a 100-millisecond pulse to 280 mV, a 300-millisecond ramp to 140 mV, and a 200-millisecond step to 0 mV before stepping back to 240 mV repeated every 4 seconds at 20-22°C. amantadine, rimantadine, and N-((5-(thiophen-2-yl)isoxazol-3-yl)methyl)-adamantan-1-amine (M2WJ352) (Wang et al., 2013b) . (B) Acylguanidines: HMA (Gazina and Petrou, 2012) , BIT-225 (Khoury et al., 2010; Luscombe et al., 2010) , EIPA, and BIT-314.
Compound Screening. Compounds were prepared in dimethylsulfoxide at 100 mM and diluted with external pH 5.5 solution to desired concentrations. To measure inhibition of M2 currents by compounds, cells were exposed repeatedly to pH o 7.4 and pH o 5.5 solutions until stable, pH-dependent inward currents were reproducibly observed. Cells were then treated with compounds at defined concentrations in pH o 5.5 solution for $2 minutes. Data are presented as percent current inhibition at a given concentration of compound or concentration required for IC 50 . All compounds were initially tested at 100 mM. Compounds that showed greater than 50% inhibition at 100 mM were further tested at lower concentrations to estimate the IC 50 . This was calculated from nonlinear regression fitting of percentage inhibition at minimum of three concentrations, and experiments were performed at least three times at each concentration.
Current-Voltage Relations. M2-transfected ltk-murine fibroblast (LM) cells were used 18-48 hours post-transfection. Cells were voltage clamped using the whole-cell patch-clamp configuration previously described herein. To maximize internal pH (pH i ) control, high concentrations of pH buffer were used as impermeant ions: the patch pipette contained 90 mM N-methyl-D-glucamine (NMDG), 10 mM EGTA, and 180 mM N-2-hydroxyethylpiperazine-N9-2-ethanesulphonic acid (HEPES). The bath contained a similar solution with 2 mM CaCl 2 replacing EGTA. The pH of all solutions was lowered to desired values by addition of 5 M aqueous HCl. The osmolality of both bath solutions (pH o 7.4 and 5.6) as well as the patch pipette solution were precisely adjusted to 300 mOsmol/kg by the addition of glucose and measured by an osmometer (OsmetteII, Precision Systems Inc., MA). Membrane current was recorded at 20-22°C, digitized at 10 kHz. Current was measured using a modified voltage ramp protocol that extended the voltage range from 280 to 1120 mV. The pH i was held constant at 7.2, whereas pH o was changed by fast perfusion close to the cell, and washout was by slow perfusion. M2 current voltage relations were determined by subtracting current at pH o 7.4, obtained during the ramp phase of the voltage protocol, from the activated M2 currents at pH o 5.6 or from current after exposure to compound 9 or amantadine at pH o 5.6. Reversal potentials (E rev ) were estimated by linear interpolation of data points of the I-V relation on each side of zero current.
Molecular Docking. Blind docking was carried out using AutoDock4.2 software (Morris et al., 1998) using the default parameters, the Lamarckian genetic algorithm with local search, and 25 million energy evaluations per run; 150 runs were performed for 9, 120 runs for 26, and 100 for 27. The solution nuclear magnetic resonance (NMR) structure of M2 (A/Hong Kong/156/97; PDB 2LY0) (Wang et al., 2013b) with N-((5-(thiophen-2-yl)isoxazol-3-yl)methyl)adamantan-1-amine (M2WJ332) removed, was used as the receptor. Autodock4.2 allows for 32 flexible bonds to be modeled; two were used for compound 9, six for compound 26, and seven for compound 27. The remaining bonds were used to allow flexibility of the side chains of Val27, Ser31, and His37. The remaining residues of the channel were held rigid during the docking process. The grid box size in initial runs were 20.25 Â 30 Â 20.25 Å in the x, y, and z dimensions, which covered Ser23 to Arg45 of the crystal structure, and was expanded to 17.62 Â 45 Â 18.75 Å in subsequent runs to include Asp21 to Lys49, both centered around the inner pore. Figures were generated using PyMOL (Schrödinger, Inc., NY) with the PyMOL Autodock Plugin (Seeliger and De Groot, 2010) .
Cytotoxicity. The tsA-201 cells were assessed for cell viability using the MTT reagent kit (Life Technologies). Cells were plated in 96-well plates (2.5 × 10 4 cells / well) and incubated for 24 hours, followed by treatment with drug for 24 hours. Cells were then incubated with MTT reagent for 4 hours and treated with an equal volume of 10% SDS 1 0.01 M HCl. Cell cultures were read by spectrophotometry at an absorbance wavelength of 570 nm (A 570 ). A 570 background values from wells without cells were subtracted from the A 570 cell culture values and normalized to the average A 570 value of cell cultures in the absence of compounds. Data were obtained from at least three experiments and at least five concentrations.
Generation of Amantadine-Sensitive and -Resistant Influenza Viruses. Recombinant influenza A viruses were generated using the reverse genetic system based on the A/Puerto Rico/8/34 (PR8) strain (Neumann et al., 1999) provided by Dr. Y. Kawaoka (University of Wisconsin, Madison). The endogenous M2 sequence of PR8 encodes both a threonine at position 27 (T27) and asparagine at position 31 (N31) that render amantadine resistance. Amantadinesensitive PR8 viruses were therefore generated by mutating T27 and N31 to valine (V27) and serine (S31), respectively. Amantadineresistant M2 encoding V27 and N31 was also generated. Nucleotide substitutions were introduced by modifying the sequence of pPol-PR8-MG-M (one of the 12 plasmids that make up the reverse genetics system) using two-step overlap extension polymerase chain reaction (PCR) and cloning of subsequent DNA fragments into the pHH21 vector. A DNA fragment containing the S31 point mutation was generated using the primers TSH289, TSH293, TSH294, and TSH292 (Supplemental Table 1 ) and pPol-PR8-HG-M (M2 T27 1 N31) as the template. The PCR fragment and pHH21 vector were then treated with restriction endonuclease BsmBI and ligated to generate pPol-PR8-HG-M-V27-N31 (M2 V27 1 N31). A DNA fragment encoding V27 and S31 was generated using the same primers and pPol-PR8-HG-M-A27-S31 (M2 A27 1 S31) as the template, which in turn was generated using primers TSH289, TSH290, TSH291, and TSH292 (Supplemental Table 1 ) and pPol-PR8-HG-M (M2 T27 1 N31) as the template, resulting in generation of pPol-PR8-HG-M-V27-S31 (M2 V27 1 S31). PCRs were performed using the Expand High Fidelity PCR System (Roche), and all constructs were confirmed by sequencing using primers TSH284 and TSH285 (Supplemental Table 1 ). Viruses were generated by transfecting one of the recombinant pPol-PR8-HG-M plasmids with the other 11 plasmids of the reverse genetics system to 293FT cells (Life Technologies). Cells were plated in a six-well plate and transfected with the plasmid mixture (250 ng each) using TransIT LT-1 (Mirus). Culture supernatants were collected 48 hours after transfection and passed through a 0.45-mm filter. After propagating virus in Madin-Darby canine kidney (MDCK) cells for three to four passages, virus stocks were stored at 280°C. Viral Cytopathic Assay. MDCK cells were cultured in Dulbecco's MEM (Life Technologies) plus 10% heat-inactivated fetal bovine serum (Hyclone), 100 U/ml penicillin, and 100 mg/ml streptomycin (Life Technologies) except during generation of virus stocks and plaque assays, when serum was removed from the media. Plaque reduction assays were carried out in triplicate as described (Song et al., 2005) with minor modifications. Briefly, approximately 100 plaque-forming units of either PR8 recombinant with M2 V27 1 S31 (PR8 M2(WT) ) or one with M2 V27 1 N31 (PR8 M2(S31N) ) mixed with different concentrations of the compounds, ranging from 100 mM to 1 mM, and inoculated on confluent MDCK monolayers in six-well plates. After a 1-hour adsorption at 37°C, the inocula were removed, and cells were washed twice with phosphate-buffered saline (PBS). The cells were then overlaid with Dulbecco's MEM containing 1% Noble agar (Affymetrix, Santa Clara, CA), 10 mM HEPES buffer (Lonza, Ververs, Belgium), 0.00075% Difco Trypsin 250 (BD Biosciences, San Jose, CA), 100 U/ml penicillin, 100 mg/ml streptomycin, and each compound at test concentration. After incubation in 5% CO 2 at 37°C for 3 days, plaques were visualized and counted by staining the cells with 0.01% Neutral Red (Sigma-Aldrich). The concentration that reduces plaque number by 50% compared with the dimethylsulfoxide control (EC 50 ) was calculated by regression analysis of the dose-response curves.
Results
Detection of M2 Currents by Whole-Cell PatchClamp Electrophysiology. We initially investigated baseline M2 ion channel activity by cotransfecting tsA-201 cells with plasmids encoding GFP and M2(WT) (A/Hong Kong/1073/99(H9N2)) and recording pH-dependent ion currents in GFP-positive cells by whole-cell patch-clamp electrophysiology ( Fig. 2 ; Chizhmakov et al., 1996; Kolocouris et al., 2014) . Cells were held at a constant membrane potential of 240 mV, and currents were recorded every 4 seconds by applying 100-millisecond pulses to 280 mV. When M2-expressing (i.e., GFP-positive) cells were incubated in solution at pH o 7.4 (designated by the horizontal black lines above each panel in Fig. 2) , minimal negative or inward current was observed (,10 pA), which was normalized to 0.0 pA after all leak and initial current changes had settled. In contrast, exposure to pH o 5.9-5.5 (designated by the horizontal white rectangles above each panel) resulted in an initially large inward current that decayed ∼50% during continued exposure to low pH o . Return to pH o 7.4 caused the steady inward current to deactivate. Subsequent repeated exposures to extracellular acid solutions reversibly activated the relatively constant level of inward current ( Fig. 2A) , consistent with previous observations (Pinto et al., 1992; Kolocouris et al., 2014) . Currents were also detected in cells transfected with M2(WT) lacking the N-terminal FLAG epitope (data not shown) but not in cells transfected with only GFP control vector (Supplemental Fig. 2 ).
Also consistent with previous reports (Pinto et al., 1992; Chizhmakov et al., 1996) , extracellular administration of amantadine inhibited M2(WT) currents at acidic pH o in a dose-dependent manner (Fig. 2B ), indicating that this protocol, which differs in cell type, M2 strain, and pulse protocol from previous electrophysiology studies (Pinto et al., 1992; Chizhmakov et al., 1996) , could be used to screen test agents for M2 current inhibition. No obvious differences were observed at pH o 5.5-5.9 in efficacy or rate of M2 inhibition by amantadine and subsequent compounds (data not shown). For all compounds tested in this study, we obtained dose-response relationships if $50% inhibition of M2 current was observed at 100 mM. For amantadine, we determined an IC 50 of 0.6 6 0.2 mM (Table 1) . Using this protocol, we then screened four acylguanidinecontaining molecules ( Fig. 1B ; Table 1 ). The most potent compound was HMA, which blocked M2(WT) currents with an IC 50 of 1.3 6 0.3 mM (Fig. 2C ), followed by EIPA, which blocked M2(WT) currents with an IC 50 of 52 6 8 mM. In contrast, both BIT-225 and BIT-314 showed only modest activity against M2(WT) (30% 6 5% and 14% 6 2% inhibition of M2(WT) at 100 mM, respectively) and were not explored further.
Synthesis of a Novel HMA Derivative with Improved Activity against M2(WT). As HMA exhibited the most activity of the acylguanidines tested against M2(WT), we next asked which functional groups of HMA were responsible for its inhibitory activity. To test initially the role of central ring substitutions, we began by replacing the central pyrazine with a phenyl ring to generate compound 1. Despite removal of the ring nitrogens, the exocyclic amino groups and the chloroatom 1 exhibited improved activity against M2(WT) (IC 50 5 0.4 6 0.1 mM). In contrast, an analog of 1 with complete removal of the seven-membered azepane ring (1-benzoylguanidine) had almost no activity (,10% block; Table 1 ), indicating that a distal moiety is required. We did find that substitution of the azepane ring with cyclohexane was somewhat tolerated for anti-M2(WT) activity (e.g., 4; IC 50 5 5.0 6 1.0 mM); however, this activity was sharply reduced when the cyclohexane was replaced with a more distally polar morpholine ring (6; 33% 6 3% inhibition at 100 mM). Moreover, substitution with a pyrrolidine, benzene, or methoxybenzene was also less tolerated (IC 50 5 50 6 10 mM for 5; 33% inhibition at 100 mM for 2 and 3). Furthermore, the residual activity of 2 was abolished when the distal ring was shifted to the ortho or meta position of the central ring relative to acylguanidine (i.e., ,10% block of M2(WT) by 100 mM of compounds 7 or 8), emphasizing the importance of ligand linearity and consistent with our observations of limited anti-M2(WT) efficacy of nonlinear molecules BIT-225 and BIT-314 (Table 1) .
We next substituted a single phenyl carbon of 1 with nitrogen and synthesized compound 9. Like 1, compound 9 was also highly potent and inhibited M2(WT) current at pH o 5.5 (Fig.  3A) , with an IC 50 of 0.2 6 0.1 mM (Table 1) . In contrast, no inhibition of pH-dependent currents from the M2 ion channel of influenza B (B/Lee/1940) (Mould et al., 2003) was observed with up to 100 mM of 9 (Fig. 3B) , demonstrating that the inhibitory activity of 9 is specific to M2 encoded by influenza A. Further structure activity studies were performed using 9. With respect to the central ring, replacing the pyridyl nitrogen with an exocyclic nitrogen in the form of a nitro group (11) also largely retained activity against M2(WT) (IC 50 5 1.8 6 0.1 mM), but shifting the central pyridyl nitrogen to the ortho position relative to the acylguanidine moiety (12) substantially reduced activity (38% 6 7% inhibition at 100 mM). Similar to the compound 1 to 1-benzoylguanidine transition, removal of the distal seven-membered azapane ring of 9 also eliminated activity (10). Moreover, removal of the guanidinium and/or carbonyl groups of the acylguanidine moiety (13, 14, 15) completely abolished or strongly reduced M2(WT) current inhibition at 100 mM (e.g., maximum 36% 6 3% inhibition for 15; Table 1 ).
Mechanisms of Action of Novel Influenza A/M2 Viroporin Inhibitors
Compound 9 exhibited the most activity against M2(WT) currents, with almost an order of magnitude improved efficacy over the parent compound HMA. Moreover, and consistent with the docking model described as follows, molecule linearity combined with the presence of acylguanidine and distal ring moieties were necessary for M2(WT) activity, although some modifications to the central and distal rings were tolerated.
Effects of Compound 9 on M2(WT) Current-Voltage Relationships. We were interested in understanding the voltage dependence of 9 effects on pure M2 conductance in mammalian cells and so carried out voltage clamp experiments in LM cells expressing M2(WT) protein. H 1 whole-cell currents were measured in the absence of other monovalent cations (Na 1 and K 1 ) using pipette and external media that contained only impermeant organic ions N-methyl Dglucamine(NMDG 1 ) and HEPES -or MES -. Consistent with results obtained from tsA-201 cells, in LM cells transfected with M2(WT), a change in pH o from 7.4 to 5.6 induced an inward current at 280 mV that was sensitive to both 9 (Fig.  4A ) and amantadine (Supplemental Fig. 3 ). Current-voltage relationships obtained during the ramp phase of the protocol between 280 and 1120 mV in pH o 7.4, 5.6, and at pH o 5.6 plus 100 mM 9 are shown in Fig. 4B . It can be seen that all three relationships cross close to 180 mV. Subtraction of the relationship obtained at pH o 7.4, which we assume contains little M2 current, from those at pH o 5.6 places the reversal potential of the pH o 5.6 relations on the zero current axis and gives an E rev of 180 mV (Fig. 4C) , which is close to the predicted reversal potential of 192 mV for a pure, M2-dependent H 1 current. Similarly, subtraction of the two relationships obtained at pH o 5.6 gave the 9-sensitive current (Fig. 4D) , which showed an E rev of 185 mV, again close to that predicted for a pure H 1 current. The S.D. of the data points around the best-fit line through the current-voltage relations at their reversal potentials was 68 mV, indicating the overall error in estimating E rev . These results suggest that lowered pH o activates a relatively pure M2 H 1 current and that 9 (Fig.  4) and amantadine (Supplemental Fig. 3 ) both directly inhibit M2 H 1 currents in these cells. Molecular Modeling of M2(WT) Block. To gain insight into how 9, 26, and 27 (described below) might bind and inhibit the M2 channel, we performed molecular docking analyses (Morris et al., 1998; Huey et al., 2007; Seeliger and De Groot, 2010) with the M2 transmembrane domain tetramer (PDB entry 2LY0, the NMR structure of residues 19-49 of M2 of A/Chiba/5/71(H3N2) in dodecylphosphocholine micelles, computationally modified to include S31 when necessary; Wang et al., 2013b) . In addition, we ran a compound that did not block in electrophysiologic studies to observe the predictions made by the program. Because of the constraints of the AutoDock 4 software that limit the number of flexible bonds in the ligand plus the receptor to 32 for accuracy (Trott and Olson, 2010) , the M2 structure was largely held rigid during docking simulations, with the exception of three flexible residues per tetramer subunit (Val27, Ser31 or Asn31, and His37). These residues were selected based on 9's interactions during a trial molecular docking simulation where M2(WT) Cells were pulsed every 6 seconds from a holding potential of 240 mV, first to 80 mV for 200 milliseconds and then ramped for 600 milliseconds to +120 mV, a 400-millisecond repolarization to 0 mV, and then back to 240 mV. A current reading was taken at 280 mV and plotted against pulse number. Cells were exposed to pH o 7.4 solution twice as denoted by the thin black bar above the graph, to pH o 5.6 during the periods denoted by the thick bars, and also to pH o 5.6 + 100 mM compound 9 (gray thick bar). Current voltage relations obtained under the three conditions at the times indicated in (A) by the symbols are plotted in (B). All three relationships show mild inward rectification but cross at ∼+80 mV. (C) Current activated at pH o 5.6, before and in the presence of 100 mM compound 9, obtained by subtracting current at pH o 7.4. (D) Compound 9-sensitive current only, obtained by subtracting relationships in pH o 5.6, before and after compound 9 exposure, E rev = +85 mV. was held entirely rigid, in addition to a visual scan for residues with side chains that were most obviously pointing into the inner vestibule and could provide steric hindrance if left rigid. Using these parameters, we identified several binding sites for 9 (Fig. 5, A-D) . Many of the lowest energy binding conformations were in the turret (Fig. 5A) , and many did not actually block the channel, suggesting this might not be the block site. This result is consistent with the fact that 9 does not block N31 ( Table 2 and described as follows), and the two share identical sequence in the turret. Autodock also predicted in some conformations that the hydrophobic seven-membered azepane ring of 9 could pass through the constriction created by the valines at position 27, whereas the acyl guanidine portion maintained polar interactions with Ser22 and Asp24, creating an effective plug of the pore (Fig. 5B) . Much of 9 block is readily reversible upon washout (Fig. 5F ), and this binding configuration might explain this reversibility since most of 9 remains outside the inner vestibule. The 20% block that is not reversible might then be a result of full entry of the drug into the inner vestibule (Fig. 5, C and D) . Approximately 50% of predicted binding conformations were in the inner vestibule, but all these fell 1 or 2 kcal/mol higher in energy than most turret binding conformations (213.61 to 211.85 kcal/mol). These could be with either the acyl guanidine pointing toward the valines (Fig. 5, C and D) or toward the histidines at position 37 (Supplemental Fig. 6 ) with similar binding energies. If the initial trajectory of the passage involves a hydrophobic interaction between the seven-membered azepane ring and the valines, this would favor an inner vestibule orientation as shown in Fig. 5C (shown in more detail in Fig.  5D ). In this conformation, the seven-membered azepane ring is reaching down to interact with histidine 37 from two subunits as well as the backbone of leucine 38. In addition, the azepane ring and the central pyridyl ring make hydrophobic interactions with Gly34 and Ala30, respectively, and the acyl guanidine interacts with valines that define the roof of the inner vestibule (Fig. 5D) .
Interestingly, mutations at multiple M2 residues predicted to interact with 9, including Val27, Ala30, and Gly34, lead to adamantane resistance in vitro or in transmissible viruses (Hay et al., 1985 (Hay et al., , 1986 Belshe et al., 1988) . Facets of the docking approach, such as use of an empirical hydration force field for the drug binding in the water-filled lumen and use of a micellar protein structure and homology model thereof, require a conservative interpretation confined to assessment of the steric fit of the drug in the pore. Nevertheless, taken together, these observations further support that 9 inhibits M2(WT), but potentially not M2(S31N), by a pore-blocking mechanism. That 9 does not block M2-N31 leads us to speculate that the extra bulk and hydrophilicity of the asparagine side chain hinders, or it makes energetically unfavorable, the entry of the bulky hydrophobic 7-membered azepane ring of 9 into the inner vestibule of the mutant channel.
As 9 and amantadine are predicted to interact with many of the same M2 pore-lining residues, we next tested whether 9 and amantadine compete for M2(WT) inhibition (Fig. 5, E-H) . Treatment of M2(WT)-expressing cells with 10 mM amantadine at pH o 5.5 reduced pH-dependent currents by 63.5% (Fig.  5E ). After removal of amantadine from extracellular solution, however, little recovery of baseline M2(WT) current was observed after either at least 3.3 minutes at pH o 5.5 (Fig.  5E ) or iterative treatment with pH o 7.4 and pH o 5.5 solutions (data not shown), consistent with previous observations that amantadine does not readily dissociate from blocked M2(WT) channels (Balannik et al., 2009 (Balannik et al., , 2010 . In contrast, although 10 mM of 9 reduced M2(WT)-dependent currents by 80.5% in Fig. 5F , these currents recovered 57.1% within 3.3 minutes of removal of 9, indicating reversible inhibition and rapid recovery of M2(WT) currents. The different M2(WT) current recovery rates observed after removal of amantadine and 9 from pH o 5.5 solution let us test which compound preferentially blocked M2 (WT) when applied in competition. As shown in Fig. 5G , when 10 mM of 9 was administered at pH o 5.5 to inhibit M2(WT) (90.5% inhibition in this example), no obvious further inhibition by 10 mM amantadine was observed. After removal of both compounds, M2(WT) current recovered by 58.0% after 5 minutes, consistent with a model where M2(WT) was inhibited primarily by 9, and amantadine was largely unable to dislodge it from the pore. These recovered M2(WT) currents were subsequently inhibited by 10 mM amantadine (data not shown), showing that removal of 9 from the pore allowed amantadine access. When 5 mM of 9 was used (Fig.  5H ), which resulted in 61% block, subsequent exposure to 10 mM amantadine caused a further reduction in current. This suggests that amantadine can access M2(WT) channels left unblocked by the lower concentration of 9. Taken together, these experiments suggest that 9 and amantadine likely compete for the same or highly overlapping binding sites to inhibit M2(WT). Activity of Compound 9 against AdamantaneResistant M2 Sequence. To assess the inhibitory potential of 9 against mutant M2 viroporins, we examined inhibition of pH o -dependent currents in tsA-201 cells expressing an A/Hong Kong/1073/99(H9N2) M2 sequence encoding S31N. pH-dependent currents from M2(S31N)-expressing cells were identical to those of cells expressing M2(WT) (Fig. 6) . Consistent with this mutation conferring adamantane resistance (Balannik et al., 2010; Williams et al., 2013) , we observed that M2(S31N) was inhibited only 24% 6 1% by 100 mM amantadine and 10% 6 3% by 100 mM HMA in patch-clamp experiments (Table 2) . Similarly, sequential exposure to 10 and 100 mM of 9 at pH o 5.5 had almost no activity on M2(S31N), as shown in Fig. 6A and Table 2 (,10% inhibition).
Discovery of HMA Derivatives with Activity against M2(S31N). M2(S31N) is the most prevalent adamantaneresistant mutation observed in transmissible influenza (Bright et al., 2005) , so we next asked if derivatives of 9 could inhibit M2(S31N). As S31N affects both the polarity and the size of the hydrophobic adamantane binding site (Wang et al., 2011; Williams et al., 2013) , we hypothesized that modifications to the hydrophobic terminus of 9 incorporating more polar groups might improve M2(S31N) inhibition, perhaps by stabilizing proximal or distal interactions within the M2(S31N) pore. We first measured whether M2(S31N) could be inhibited by compounds 6, 16, 18, and 20, all of which contain polar substituents in the distal ring; however, these compounds had little or no activity at 100 mM (e.g., maximum 16% 6 4% inhibition for 16; Table 2 ). Furthermore, 100 mM 1 and 11 also had limited or no activity against M2(S31N) (e.g., maximum 10% 6 1% inhibition for 11; Table 2 ), indicating that these central ring modifications, on their own, did not substantially improve activity against M2(S31N).
We then assessed the combined effects of a more polar, tertbutyloxycarbonyl (Boc)-conjugated distal piperazine (i.e., 16) with a polar nitro group on the central ring (i.e., 11). Interestingly, this compound (28) inhibited M2(S31N) with slightly more than additive effects relative to 16 and 11 (32% 6 5% at 100 mM; Table 2 ), indicating that both the nitro and terminal Boc groups of the piperazine are needed for M2(S31N) inhibition; however, 28 did not inhibit M2(WT). This observation, combined with activity against M2(S31N), which is only slightly improved over amantadine, prompted us to continue exploring 28 derivatives with improved M2(S31N) and M2(WT) activities.
After our identification of 28 as an early lead for M2(S31N) inhibition, we next found that substitution of the central ring nitro group with either a chlorine (23) or nitrile (22) reduced activity against M2(S31N) (,10% and 17% 6 8% at 100 mM, respectively). Shifting of the nitro group to ortho-position with regard to the acylguanidine moiety (17) also reduced activity (10% 6 5% at 100 mM). Activity against M2(S31N) was also eliminated by increasing the size of the second ring from piperazine (28) to homopiperazine (21), with inhibition less than 10% at 100 mM. Finally, compounds with different size carboxylates (29 and 32) and sulfonamide (31) did not exhibit potent activity against M2(S31N) (maximum 11% 6 8% at 100 mM); however, switching the Boc-conjugated piperazine (28) with a piperidine ring with a slightly more polar terminal group (25) resulted in a compound having the same level of efficacy. Replacing the heterocyclic ring with an aromatic ring (26) substantially improved activity against M2(S31N) (60% 6 7% at 100 mM; IC 50 5 42 6 5 mM; Fig. 6B ). Unlike 28, compound 26 also had observable, albeit weak activity against M2(WT) (20% 6 5% inhibition at 100 mM; Fig. 6C ). Further substitution of a polar nitro group into the distal ring resulted in compound 27, which had even more activity against both M2(WT) and M2(S31N), with IC 50 s of 0.6 mM and 4.4 mM, respectively.
In this way, we identified multiple derivatives of 9 that inhibit M2(S31N) currents, with lead compounds 26 and 27 inhibiting M2(S31N) with greatly improved activity over HMA and amantadine while retaining submicromolar M2(WT) activity in the case of 27. As whole-cell patch clamp electrophysiology and TEVC are not directly comparable, we synthesized M2WJ352 (Wang et al., 2013b) , a potent adamantane derivative, and found its IC 50 to be 44 mM (Table 2) , some 10-fold weaker than 27. Molecular Docking Studies of M2(S31N) Block by 26 and 27. When molecular docking studies were performed with 26 within the M2(S31N) pore, two confirmations with inverse orientations were again observed to interact with Val27, Ala30, Gly34, His37, and Leu38, along with Asn31 (Fig.  6, D and E) ; however, similar to 9, the orientation of the acylguanidine differed by interacting with either one or more of the valines at position 27 (Fig. 6D ) or by interacting with the histidines of the proton sensor (Fig. 6E) . Both the guanidine amines and the oxygens of the nitro-substituted phenyl ring could form hydrogen bonds, as shown in Fig. 6D . Also, in some conformations (still within 2.0 RMSD), the oxygens of the Boc terminal group contributed to hydrogen bonding with His37 or Asn31 (data not shown). Taken together, in comparison with 9, the longer molecule of 26, with added bulk and polarity of both the nitro and Boc group, may help stabilize interactions across more of the pore, thereby improving block against M2(S31N).
Whereas 26 does not bind in the turret, the variety of conformations observed for this compound was no less impressive than for 9 ( Supplemental Fig. 4) . The compound could are the valines at position 27 (indicated by arrows for two subunits) and the histidines at position 37 that create the narrowing in the distance. (Bii) Same conformation as in (i). This time, residues of the channel interacting with 14 are represented by mesh spheres, and the rest of the channel is in stick form. Labeled residues are those that are flexible (Val27, Asn31, and His37) for orientation purposes, as well as those interacting with 14.
be found in an orientation with the acyl guanidine, pointing toward the extracellular domain ( Fig. 6D; Supplemental Fig.  4B ) or cytoplasmically ( Fig. 6E; Supplemental Fig. 4A ) and at varying depths within the M2 pore. It is conceivable that since the lowest energy conformations are deeper in the pore (Fig. 6 , D and E; Supplemental Fig. 4A, B, far left) , the other conformations are intermediate states of the compound as it progresses to a preferred binding site, although all of the conformations lead to block. That 26 does not wash out upon solution change (data not shown) leads one to speculate that once at least the bulk of the drug is past the valine ring, it is difficult to reverse the entry process.
The binding patterns for 27 were fairly similar whether there was a serine at position 31 or an asparagine. Averaged over many runs for each channel construct, Val27 was occupied ∼67% of the time, Ala30 ∼47%, Ser/Asn31 ∼27%, and Gly34 ∼16%. Again, compound 27 was found to bind the channel in "Boc up" or "Boc down" conformations. When Serine was present at position 31, the lower-energy cluster was Boc up (Fig. 7Ai) ; Supplemental Fig. 5A ), although 63% of the runs fell into one of the Boc down conformations. When asparagine was present, the lower energy clusters were Boc down, and 54% of runs fell into these two clusters (Fig. 7Aiii,  iv) ; Supplemental Fig. 5B ). The lowest-energy conformation found in M2(N31) was almost a kcal/mol more than the lowest energy conformation found when serine was present, which is consistent with the electrophysiologic data showing 27 to be almost 10 times more effective in blocking the WT channel (Tables 1 and 2 ).
The nitro-substituted phenyl rings tended to interact with the hydrophobic wall of the inner vestibule, Val27, Ala30, Ile33, and Gly34. The nitro groups on these phenyl rings interacted with serine or asparagine and even histidine if the drug bound low enough in the pore, and occasionally hydrogen bonds were predicted (Fig. 7Aiv) . When 27 bound residues in the turret, hydrogen bonds were much more common between the acyl guanidine hydrogens and the oxygens of Asp21, Ser22, Ser23, and Asp24. The Boc group made hydrophobic interactions, depending on the depth and orientation, with the carbons in the histidine side chains (Fig. 7Aii,iv) , or with Ala30 and Val27 (Fig. 7Ai,iii) . Given that the Boc group presents a hydrophobic terminus, it is tempting to speculate that it is this end that would pass through the valine ring more readily and that the Boc-down orientation might be favored. Adding the bulkier, more hydrophilic asparagine just below the valine might make entry slightly less favorable.
Molecular Docking of Compound 14 onto M2. Compound 14 is one that failed to block M2(WT) at 100 mM (,10%, Table 1 ), and modeling frequently predicted that 14 would bind in the extracellular turret (Fig. 7B ) without blocking the channel with very low binding energy (217.16 kcal/mol). Interactions were made with Asp21, Ser22, Ser23, Asp24, and sometimes with one of the valines, often with the amine hydrogens forming hydrogen bonds with the aspartic acid oxygens. It is likely possible that more than one molecule of 14 could in fact bind in the turret given the 4-fold symmetry of the channel. Even in this situation, given that the compound is off the central axis of the pore, there would be no block. Where a binding site was found in the internal vestibule, the lowerenergy conformations were almost 2 kcal/mol higher in energy than the turret site (215.41 kcal/mol; not shown). Migration into the inner vestibule would require the high-affinity turret site to remain vacant to allow an additional molecule of 14 to pass; 14 is a smaller molecule than 9, 26, and 27. It lacks the acyl guanidine of 9, 26, and 27 that provides bulk and length and the nitro groups bulking up the rings of 26 and 27. It is likely for this reason that when 14 binds the channel, it can fail to block the channel (Fig. 7B) .
In Vitro Cytotoxicity. Compounds that inhibited .50% of M2(WT) or .30% of M2(S31N) currents at 100 mM were assessed for cytotoxicity. Using a standard MTT-based cell metabolic assay, no obvious effects were observed in tsA-201 cells incubated for 24 hours with up to 100 mM amantadine, M2WJ352, or compound 9 (Table 1 ). In contrast, HMA inhibited growth of tsA-201 cells with a 50% cytotoxic concentration of 4.7 6 0.3 mM. Thus, although HMA inhibits M2(S31) currents with efficacy comparable to that of the established inhibitor amantadine and 9, it also has undesirable cellular toxicity consistent with previous observations (Balgi et al., 2013) . Intermediate levels of cytotoxicity between HMA and 9 were observed for both inhibitors of M2(S31N) and other 9 derivatives (e.g., 50% cytotoxic concentration 5 25 6 5 mM for 26, 55, 6 17 mM for 27; Table 2 ).
In Vitro Activities against Influenza Viruses in a Cytopathic Assay. As functional experiments were primarily performed up to this point on heterologously expressed M2 ion channels, we next determined the effects of select compounds on replication of influenza A virus in vitro using a viral cytopathic assay with MDCK cells (Table 3) . Here, we used a previously described reverse genetic system based on the A/Puerto Rico/8/34 (PR8) strain (Neumann et al.., 1999) to generate PR8 strains encoding M2 with exclusively S31 (PR8 M2(WT) , containing both V27 and S31) or N31 (PR8 M2(S31N) containing V27 and N31). As expected, amantadine exhibited antiviral activity against PR8 M2(WT) but not PR8 M2(S31N) in these assays EC 50 ,1 mM for PR8 M2(WT) vs. .100 mM for PR8 M2(S31N) ; Table 3 ). Compound 9 also inhibited PR8 M2(WT) (EC 50 5 2.3 6 0.1 mM), consistent with results from patchclamp studies using M2(WT). Notably, 9 also exhibited ∼10-fold weaker activity against PR8 M2(S31N) (EC 50 5 23 6 5 mM). As 9 did not inhibit M2(S31N) currents at up to 100 mM, these observations suggest that compound 9 may have an additional antiviral mechanism besides 2(WT) blockade. Although off-target antiviral effects are frequently observed for multiple M2 inhibitors (Kolocouris et al., 2014) , the disproportionate ability of 9 to inhibit PR8 M2(WT) relative to PR8 M2(S31N) replication is nevertheless consistent with its ability to exclusively inhibit M2(WT) in patch-clamp studies and further suggests that the additional efficacy of compound 9 against PR8 M2(WT) relative to PR8 M2(S31N) is due to M2 blockade. The previously described M2(S31N) inhibitor M2WJ352 (Wang et al., 2013b) inhibited PR8 M2(S31N) with an EC 50 5 1.8 6 0.7 mM, and with a ∼19-fold reduced activity against PR8 M2(WT) (EC 50 5 34 6 6 mM). As M2WJ352 did not inhibit M2(WT) currents at up to 100 mM, these observations suggest that M2WJ352, like 9, may have antiviral mechanisms in addition to M2(S31N) blockade. Similarly, PR8 M2(S31N) replication was blocked by both 26 and 27 (EC 50 vs. PR8 M2(S31N) 5 1.5 6 0.1 mM and 18 6 1 mM, respectively) but weaker activity against PR8 M2(WT) was also observed (EC 50 vs. PR8 M2(WT) 5 6.9 6 1.6 mM and 40 6 1 mM, respectively; Table 3 ). Although the antiviral activity of 26 is consistent with electrophysiology studies, antiviral and electrophysiology profiles of 27 are discordant; thus, the antiviral activity of 27 observed here is unlikely to be due primarily to M2 blockade. Finally, no obvious cellular toxicities in MDCK cells were observed for any tested compound with the exception of 26, where clear cell death was observed only at higher concentrations (100 mM).
Discussion
Here we showed that of four acylguanidine compounds previously reported to act against multiple viroporins or viruses (Gazina and Petrou, 2012) , HMA had the most potent efficacy against influenza A M2(WT) currents, as measured by whole-cell patch-clamp electrophysiology. We then showed that the HMA derivative 9 inhibits M2(WT) and has improved efficacy over amantadine and HMA, whereas inhibition of adamantane-resistant M2(S31N) can be achieved with other derivatives of this chemical class, such as 26 and 27. Using a combination of electrophysiologic, molecular docking and structure-activity relationship studies, we identified the transmembrane pore of the M2 tetramer as the likely interaction site of 9, 26, and 27, which leads to M2 current block in a region that overlaps the reported adamantane interaction site.
Mechanisms of Block of M2(WT). The M2 protein can transfer protons selectively across membranes with a H 1 electrochemical gradient, a property consistent with its role in modifying virion and trans-Golgi pH during virus infection (Sugrue et al., 1990; Alvarado-Facundo et al., 2015) . In LM cells expressing the M2 protein, with pH i 7.2 and pH o 5.6, the I-V plots were similar in conductance and shape across all transfected cells. The inhibitory effect of amantadine (Supplemental Fig. 3 ) and 9 (Fig. 4) brought about an identical compression of the current across all voltages, whereas the pH-and drug-dependent currents through M2 demonstrated a reversal potential close to the equilibrium potential for the transmembrane pH gradient at pH o 5.6, suggesting that 9 and amantadine inhibited proton currents similarly in our experiments. Our initial molecular docking studies predicted that, in the lowest-energy state, 9 interacts within the M2(WT) pore in two different orientations ( Fig. 5; Supplemental Fig. 6 ) in a manner reminiscent of the previously described orientations of rimantadine and amantadine. Whereas alternative models of 9-M2(WT) interactions are clearly possible, our model is supported by the competition of 9 with amantadine for M2(WT) inhibition (Fig. 5) , similar effects on current-voltage relations, and the inability of 9 to inhibit currents from adamantane-resistant M2(S31N) (Fig. 6A) . Our structureactivity relationship study also identifies distinct moieties of 9 that are required to maintain anti-M2(WT) activity. For example, derivatives of 9 lacking portions of the acylguanidine group (e.g., 13, 14, and 15) were less effective in inhibiting M2(WT), whereas removal of the azepane ring (compounds 10 and 1-benzoylguanidine) or substitution with smaller rings (compounds 2, 3, 4, 5, and 6) did not improve on the activity of 9 (Table 1) . A linear molecule was also required for activity, as shifting of the distal ring to either ortho or meta position relative to the acylguanidine also eliminated activity (7, 8) . Some, but not all, compounds with substitutions in the central pyridyl ring maintained activity against M2(WT) (e.g., 1 and 11), but 9 retained the most potent inhibition of M2(WT) of the novel compounds tested here; however, 9 was ineffective in blocking the adamantane-resistant M2(S31N) variant. We then envisioned that the polarity changes brought about by the S31N mutation would require a molecule with both a more distal polar end, as well as a polar substitution on the central ring, and 28 bearing a Boc distal end and a nitro-substituted central ring appeared to bind and block the S31N mutant.
Mechanisms of Block of M2(S31N). Compared with amantadine, 28, and 25 somewhat improved blockade of currents from adamantane-resistant M2(S31N) (32%-33% inhibition at 100 mM). We did, however, identify two other HMA derivatives, 26 and 27, of which 26 showed improved potency against M2(S31N) with an IC 50 of 42 6 5 mM and weak activity against M2(WT), whereas 27 exhibited a potent dual inhibitory effect against both M2(WT), as well as M2(S31N), with an IC 50 of 4.4 6 0.5 mM and 0.6 6 0.1, respectively, as measured by whole-cell patch clamp (Tables 1  and 2 ). Autodock predicts binding of 26 in S31 that would lead to block, and so the failure to see significant block in the electrophysiologic experiments suggests that forces driving the drug into the pore are different between S31 and N31. The addition of the second set of oxygens on the second ring structure in 27 appears to overcome this. The overall orientation of 26 and 27 with M2(S31N) is, to a first approximation, similar to that of 9 with M2(WT); 26, 27, and 9 are predicted to enter their binding site in two orientations to interact variably with both the selectivity filter (Val27) and the proton sensor (His37) (Fig. 5, A D and E) . The binding site for 26 and 27 is predicted to span from Val27 to His37 (Figs. 6 and 7; Supplemental Figs. 4 and 5) , which also overlaps to a degree with the binding site previously reported by NMR for the less potent inhibitor M2WJ332 (Wang et al., 2013b) . Notably, the acylguanidine carbonyl of 9, 26, and 27 may contribute to an H-bond with Ser31 in M2(WT) (for 9) or Val27 in M2(S31N) (for 26 and 27), and removal of this acylguanidine carbonyl, as seen in compounds 14 and 15, significantly reduced activity against M2(WT). Thus the ability of 26 and 27 to act on M2(S31N) appears to be driven primarily by the presence of the acylguanidine moiety, the second aromatic ring, an additional distal Boc group, and the central ring nitro, which increase bulk and perhaps stabilize deeper interactions within the expanded M2(S31N) pore. The second aromatic ring of 26 (compared with 28 with a piperazine ring) appears to play a critical role in further stabilizing hydrophobic interactions with the walls of the amphipathic pore.
Correlation of Viral and Electrophysiology Assays. Interestingly, in viral assays (Table 3) , both amantadine and 9 displayed significant activity against PR8 M2(WT) , but not PR8 M2(S31N) virus, supporting that 9 targets this virus, at least in part, by inhibiting proton flux through M2. In contrast, both M2WJ352 and 26 were more potent against PR8 M2(S31N) , further supporting their action against M2(S31N). We note that the limited ability of 9 to inhibit PR8 M2(S31N) and 26 to inhibit PR8 M2(WT) electrophysiologically, but significant antiviral activity against these isoforms, suggests that effects of the M2 block may be amplified in vitro or indeed that these acylguanidine-based compounds may exhibit additional antiviral mechanisms, as previously suggested for adamantanes (Kolocouris et al., 2014) . Notably, compounds 9, 26, and 27 also exhibited markedly reduced cytotoxicity compared with the parent compound HMA in MTT assays with tsA-201 cells, further suggesting that these compounds may be improved starting points for future antivirals compared with HMA.
In summary, we describe novel acylguanidine-containing inhibitors of M2 viroporins with binding mechanisms similar to adamantanes, with potent activity against WT and adamantane-resistant M2 ion channels and viruses. The novel HMA derivatives, including compounds 26 and 27 as dual inhibitors of both M2(WT) and M2(S31N), provide scaffolds that may aid in development of further non-adamantane compounds with improved inhibitory activity against drugresistant forms of M2. These promising leads for additional medicinal chemistry optimization will also require further in vivo studies to assess their antiviral efficacy, stability, and pharmacokinetic parameters in animal disease models.
